Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) EBIT (2016 - 2026)

Pharma-Bio Serv's EBIT history spans 17 years, with the latest figure at -$94535.0 for Q1 2026.

  • For Q1 2026, EBIT fell 2.54% year-over-year to -$94535.0; the TTM value through Jan 2026 reached -$640006.0, up 32.02%, while the annual FY2025 figure was -$637662.0, 50.48% up from the prior year.
  • EBIT reached -$94535.0 in Q1 2026 per PBSV's latest filing, up from -$133272.0 in the prior quarter.
  • In the past five years, EBIT ranged from a high of $460466.0 in Q3 2023 to a low of -$438300.0 in Q1 2024.
  • Average EBIT over 5 years is $16033.6, with a median of -$92191.0 recorded in 2025.
  • Peak YoY movement for EBIT: soared 103.52% in 2022, then plummeted 233.37% in 2024.
  • A 5-year view of EBIT shows it stood at $168962.0 in 2022, then plummeted by 130.64% to -$51765.0 in 2023, then tumbled by 197.75% to -$154130.0 in 2024, then grew by 13.53% to -$133272.0 in 2025, then rose by 29.07% to -$94535.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's EBIT are -$94535.0 (Q1 2026), -$133272.0 (Q4 2025), and -$313877.0 (Q3 2025).